Abstract
In Japan, systems for the regulatory review of radiopharmaceuticals have lagged behind the rest of the world. Beginning around 2000, the regulatory review of radiopharmaceuticals required a rigorous and time-consuming process, which led to a decrease in the number of applications filed thereafter. As a result, Japan has relied on foreign imports for all its therapeutic—and, for that matter, diagnostic—radiopharmaceuticals. Indeed, all clinical trials during this period have focused on using Japanese subjects to evaluate imported radiopharmaceuticals that have been approved abroad. Historically, no major or international clinical trials had been conducted on Japan-made radiopharmaceuticals until 2018, and few preclinical studies been conducted as well. Therefore, significant knowledge gaps exist with respect to both the research and development (R&D) of radiopharmaceuticals and their regulatory review and approval. In Japan, the disposal of low levels of radioactive materials from laboratories and hospital rooms is regulated strictly by the Act on the Regulation of Radioisotopes (RI) and the Medical Care Act, which has resulted in several problems, including a shortage of Good Laboratory Practice (GLP) facilities. Recently, several new therapeutic agents for radiopharmaceutical therapy (RPT) have been developed. In 2018, for example, National Institutes for Quantum Science and Technology (QST) started a physician-led clinical trial of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu(ATSM)), a Japan-made radiopharmaceutical. Two physician-led clinical trials of alpha-emitting radiotherapeutics have been started as well. In 2022, the Japanese government issued a National Action Plan to wean the country off radiopharmaceuticals from overseas, and progress in the regulation of radiopharmaceuticals is expected soon.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Subcommittee on Survey of Nuclear Medicine Practice in Japan. The present state of nuclear medicine practice in Japan~a report of the 8th nationwide survey in 2017. Radioisotopes. 2018;67:339–87. (in Japanese)
Cabinet Office, Government of Japan: Title of subordinate document of Japan Atomic Energy Commission. In: Action plan for “Stable supply of technetium preparations in Japan”. 2011. https://wwwa.cao.go.jp/oaep/mo-supply/houkokusho.pdf (in Japanese). Accessed 7 July 2011.
Japanese Society of Nuclear Medicine/PET Nuclear Medicine Subcommittee: PET Facility List. https://jcpet.jp/ (in Japanese).
Advanced Accelerator Applications: A Novartis Company. https://www.adacap.com/advanced-accelerator-applications-announces-fda-approval-of-netspot-somakit-tate-a-kit-for-the-preparation-of-gallium-ga-68-dotatate-for-neuroendocrine-tumor-detection-netspot-w/
U.S.A. FOOD & DRUG Administration: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer
TELIX Pharmaceuticals Japan K.K. https://jp.telixpharma.com/news-media/%e5%89%8d%e7%ab%8b%e8%85%ba%e3%81%8c%e3%82%93pet%e7%94%bb%e5%83%8f%e8%a8%ba%e6%96%ad%e8%96%ac%e3%81%ae%e5%9b%bd%e5%86%85%e5%8c%bb%e5%b8%ab%e4%b8%bb%e5%b0%8e%e6%b2%bb%e9%a8%93%e7%b5%84%e3%81%bf/ (in Japanese).
National Institutes for Quantum Science and Technology: Succeeded in formulating a Japanese radiotherapy drug for malignant brain tumors. https://www.qst.go.jp/site/press/1214.html (in Japanese).
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4.
Radchenko V, Morgenstern A, Jalilian AR, Ramogida CF, Cutler C, Duchemin C, et al. Production and supply of a-particle–emitting radionuclides for targeted a-therapy. J Nucl Med. 2021;62:1495–503.
Nagatsu K, Suzuki H, Fukada M, Ito T, Ichinose J, Honda Y, et al. Cyclotron production of 225Ac from an electroplated 226Ra target. Eur J Nucl Med Mol Imaging. 2021;49:279–89.
Nagatsu K, Minegishi K, Fukada M, Suzuki H, Hasegawa S, Zhang M-R, et al. Production of (211)At by a vertical beam irradiation method. Appl Radiat Isot. 2014;94:363–71.
Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, Sakashita T, et al. Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging. 2018;45:999–1010.
Sudo H, Tsuji AB, Sugyo A, Nagatsu K, Minegishi K, Ishioka NS, et al. Preclinical evaluation of the acute radiotoxicity of the alpha-emitting molecular-targeted therapeutic agent (211)At-MABG for the treatment of malignant pheochromocytoma in normal mice. Transl Oncol. 2019;12:879–88.
Department of Nuclear Medicine and Tracer Kinetics: Osaka University Graduate School of Medicine. News Release. https://www.med.osaka-u.ac.jp/pub/tracer/about/research/nuclear_01.html (in Japanese).
Bayer Development Pipeline: https://www.bayer.com/en/pharma/development-pipeline
OECD Good Laboratory Practice (GLP): https://www.oecd.org/chemicalsafety/testing/good-laboratory-practiceglp.htm
WHO Health product and policy standards: Good Manufacturing Practices. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/gmp
Good Clinical Practice NETWORK. https://ichgcp.net/.
The Japanese Society of Nuclear Medicine. General Guidelines for Molecular Imaging and List of Documents Related to Drug Manufacturing. (October 7, 2021). http://jsnm.org/useful/molecule/documents/ (in Japanese).
Application of the Concepts of Exclusion, Exemption and Clearance by International Atomic Energy Agency. IAEA Safety Standards Series. STI/PUB/1202 ¦ 92-0-109404-3.
ICRP. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34(2):v–vi.
Thyroid RI Treatment Committee of Japanese Society of Nuclear Medicine in Oncology and Immunology. Subcommittee of Japanese society of Nuclear Medicine. Survey report on the operating status of RI treatment rooms in radioiodine internal therapy for thyroid cancer (5th report). Kaku Igaku. 2019;56:107–16. (in Japanese)
Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52(5):683–9.
Ministry of Health, Labor and Welfare Research Fund/Regional Medical Infrastructure Development Promotion Research Project “Research for establishing standards for radiation protection for new and existing radiation medical care” (19IA1004). https://www.mhlw.go.jp/seisakunitsuite/bunya/hokabunya/kenkyujigyou/hojokin-koubo-2021/gaiyo/19.html (in Japanese).
Ministry of Health, Labor and Welfare: Medical Administration: Health Policy Publication No.0819 No. 1 “About the exit of patients who received radiopharmaceuticals”. https://www.jrias.or.jp/pdf/iseichihatu0819_01.pdf (in Japanese) (2021). Accessed 19 Aug 2021.
Ministry of Health, Labor and Welfare. Health Publication No. 0731No. 1 “Maintenance of Cancer Treatment Cooperation Base Hospitals”. https://www.mhlw.go.jp/content/000347080.pdf (in Japanese) (2018). Accessed 31 July 2018.
Kimura T, Sakahara H, Higashi T, Honda T, Konishi J, Hosotani R, et al. Survey report on the operating status of RI treatment rooms in radioiodine internal therapy for thyroid cancer (5th report). Kaku Igaku. 2019;56:107–16. (in Japanese)
Kurita Y, Kuwahara T, Mizuno N, Okuno N, Matsumoto S, Torisima K, et al. Utility of somatostatin receptor scintigraphy in pancreatic neuroendocrine neoplasms. Suizo. 2019;34:78–85. https://doi.org/10.2958/suizo.34.78. (in Japanese)
Ministry of Health, Labor and Welfare: Notification of Chief of Examination and Management Division, Pharmaceutical and Food Safety Bureau: No. 0603001 “Guidance on the implementation of Microdose clinical trials” (June 3, 2008). https://www.pmda.go.jp/files/000206215.pdf (in Japanese).
Ministry of Health, Labor and Welfare. Ministry of Health, Labor and Welfare Ordinance No. 17. “Clinical Research Law Enforcement Regulations” (February 28, 2018). https://www.mhlw.go.jp/web/t_doc?dataId=80ab6260&dataType=0&pageNo=1 (in Japanese).
Japanese Society of Nuclear Medicine. “General Guidelines for Molecular Imaging and List of Documents Related to Drug Manufacturing” (October 7, 2021). http://jsnm.org/useful/molecule/documents/
Hachisuka A, Higashi T, Hosono M, Ono M, Uehara T, Nishimura N, et al. Japanese translation and supplementary explanation of the FDA guidance “oncology therapeutic radiopharmaceuticals: nonclinical studies and Labeling recommendations guidance for industry”. Regul Sci. 2022;12:161–77. https://doi.org/10.14982/rsmp.12.161. (in Japanese)
Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and Medical Devices Agency No. 0316001. (March 16, 2017) “Regarding partial revision of the implementation guidelines for regulatory affairs strategy consultation” https://www.pmda.go.jp/files/000217709.pdf (in Japanese).
Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38(7):1155–60.
National Institutes for Quantum Science and Technology. Title of subordinate document. In: “Succeeded in formulating a Japanese radiotherapy drug for malignant brain tumors”. https://www.qst.go.jp/site/press/1214.html (in Japanese).
Osaka University. Press release of thyroid cancer treatment with alpha-ray nuclide astatine (NaAt) https://www.med.osaka-u.ac.jp/pub/tracer/about/research/nuclear_01.html (in Japanese).
Sudo H, Tsuji AB, Sugyo A, et al. Preclinical evaluation of Podoplanin-targeted alpha-Radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma. Cell. 2021;10:2503.
Homepage of Japan Atomic Energy Commission. Radioisotope manufacturing and utilization subcommittee for medical use, etc.. http://www.aec.go.jp/jicst/NC/senmon/radioisotope/index.htm (in Japanese).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Higashi, T. (2023). The Regulatory Review of Radiotherapeutics: A Japanese Perspective. In: Bodei, L., Lewis, J.S., Zeglis, B.M. (eds) Radiopharmaceutical Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-39005-0_27
Download citation
DOI: https://doi.org/10.1007/978-3-031-39005-0_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-39004-3
Online ISBN: 978-3-031-39005-0
eBook Packages: Biomedical and Life Sciences